Epigenetic therapy with histone deacetylase (HDAC) inhibitors is worth pursuing in hormone receptor positive advanced breast cancer, suggests a phase III trial reported today at the ESMO 2018 Congress in Munich. Endocrine therapies are the foundation of treatment for patients with hormone receptor positive breast cancer. However, resistance to endocrine therapy is common, leading to […]